Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...